Claims
- 1. A compound represented by the following formula, its pharmaceutically acceptable salt or hydrates thereof
- 2. A compound represented by the following formula, its pharmaceutically acceptable salt or hydrates thereof
- 3. The compound as claimed in one of claims 1 and 2, wherein R1 is a hydrogen atom.
- 4. The compound as claimed in one of claims 1 and 2, wherein R4 is ethyl.
- 5. The compound as claimed in one of claims 1 and 2, wherein B is phenyl, pyridyl, phenyloxy, or pyridyloxy, each of which may be substituted by up to three substituents selected from the group consisting of halogen atoms, lower alkoxy groups, halogenated lower alkyl groups, hydroxy lower alkyl groups, dihydroxy lower alkyl groups, lower alkoxy(hydroxy)alkyl groups, lower alkoxy(hydroxy)alkoxy groups, lower alkoxyalkyl groups, lower alkoxyalkoxy groups, hydroxy lower alkoxy groups, dihydroxy lower alkoxy groups, lower cycloalkyl (hydroxy) alkyl groups, cyano groups, N-lower alkylaminosulfonyl groups, N-lower cycloalkylaminosulfonyl groups, lower acylalkyl groups, hydroxytetrahydropyranyl groups, lower acylaminoalkyl groups, 4-morpholinylsulfonyl groups, hydroxy lower cycloalkyl groups ω,ω-lower alkylenedioxyalkoxy groups, hydroxy lower acylamino groups, lower alkylsulfonylamino groups, halogenated lower alkoxy groups, cyano lower alkoxy groups, N,N-di lower alkylaminoalkoxy groups, and lower acylalkoxy groups.
- 6. The compound as claimed in one of claims 1 and 2, wherein B is phenyl, pyridyl, phenyloxy, or pyridyloxy, each of which may be substituted by up to three substituents selected from the group consisting of lower alkoxy(hydroxy)alkoxy groups, lower alkoxyalkoxy groups, hydroxy lower alkoxy groups, and dihydroxy lower alkoxy groups.
- 7. A pharmaceutical composition which comprises a pharmaceutically effective dose of the compound as claimed in claim 1 or 2, its pharmaceutically acceptable salt or hydrates thereof, and pharmaceutically acceptable carriers.
- 8. A pharmaceutical composition for treating or ameliorating spastic paralysis, which comprises the compound as claimed in claim 1 or 2, its pharmaceutically acceptable salt or hydrates thereof as the active ingredient, in association with a pharmaceutically acceptable carrier.
- 9. A pharmaceutical composition for use as a muscle relaxant, which comprises the compound as claimed in claim 1 or 2, its pharmaceutically acceptable salt or hydrates thereof as the active ingredient, in association with a pharmaceutically acceptable carrier.
- 10. A method for treating spastic paralysis or for ameliorating myotonia, which comprising the step of administering to a patient a pharmaceutically effective dose of the compound as claimed in claim 1 or 2, its pharmaceutically acceptable salt or hydrates thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9-284290 |
Oct 1997 |
JP |
|
Parent Case Info
[0001] This application is a divisional of co-pending application Ser. No. 09/852,850, filed May 11, 2001, which is a divisional of Ser. No. 09/509,778, filed on Mar. 31, 2000 (now U.S. Pat. No. 6,340,759B1) and for which priority is claimed under 35 U.S.C. § 120. application Ser. No. 09/509,778 is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP98/04465 filed on Oct. 2, 1998. The entire contents of each of the above-identified applications is hereby incorporated by reference. This application also. Claims priority under 35 U.S.C. § 119 to Application No. 9-284290 filed in Japan on Oct. 2, 1997.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09852850 |
May 2001 |
US |
Child |
10796673 |
Mar 2004 |
US |
Parent |
09509778 |
Mar 2000 |
US |
Child |
09852850 |
May 2001 |
US |